Antitope & Synthon Announce Collaboration
Antitope Limited recently announced it will collaborate with Synthon Biopharmaceuticals BV to assess the potential immunogenicity of candidate antibodies for Synthon’s ADC programs.
Antitope will use its EpiScreen technology, a highly accurate and sensitive ex vivo human T cell assay to determine the potential immunogenicity of the antibodies provided by Synthon. The EpiScreen technology correlates with published clinical anti-drug antibody immunogenicity data, which supports selection of lead product candidates with low immunogenicity during preclinical development.
“We are confident that Antitope’s EpiScreen technology will strongly help reduce the risk that Synthon’s antibody-based development candidates will induce immunogenic responses in patient populations,” said Marco Timmers, CSO of Synthon Biopharmaceuticals.
“We are very pleased to be working with a company that, like Abzena, has scientific innovation at the heart of its business and look forward to collaborating with Synthon to help it build its biopharmaceuticals pipeline,” added Matthew Baker, CSO of the Abzena group and Co-founder of Antitope.
Antitope is a wholly owned subsidiary of Abzena Limited, a group focused on providing proprietary technologies and value-added services to enable the development of better biopharmaceuticals. For more information, visit www.antitope.co.uk.
Abzena is focused on providing proprietary technologies and value-added services to enable the development of better biopharmaceuticals. Abzena comprises two wholly owned subsidiary businesses – PolyTherics and Antitope – which have established a broad suite of complementary technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits. For more information, visit www.abzena.com.
Synthon, with headquarters in Nijmegen, The Netherlands, is an international pharmaceutical company and a leader in the field of generic medicines. The company started its biopharmaceutical franchise in 2007 and is building a promising portfolio of next-generation medicines. For more information, visit www.synthon.com.
Total Page Views: 1155
